Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK.
Clin Genet. 2013 Apr;83(4):297-306. doi: 10.1111/cge.12055. Epub 2012 Dec 4.
The increasing worldwide prevalence of type 2 diabetes (T2D) motivates efforts to use genetics to define key pathways involved in disease predisposition, and thereby to improve management of the disease. Research over the past 5 years has taken the total number of genetic loci implicated in T2D susceptibility beyond 60, and the emphasis is now shifting to the translation of these genetic insights into clinical value. Clinical translation may flow from the identification of novel therapeutic targets, but opportunities also exist with respect to individual prediction, diagnostic biomarkers and therapeutic optimization. To date, the main clinical impact has been seen for relatively rare, monogenic forms of diabetes rather than common T2D. However, the advent of high throughput sequencing approaches may herald discovery of rare and low frequency variants that offer greater translational potential.
全球 2 型糖尿病(T2D)的发病率不断上升,促使人们努力利用遗传学来确定疾病易感性相关的关键途径,从而改善疾病的管理。过去 5 年的研究使涉及 T2D 易感性的遗传位点总数超过 60 个,现在的重点正在转向将这些遗传见解转化为临床价值。临床转化可能源于对新型治疗靶点的识别,但在个体预测、诊断生物标志物和治疗优化方面也存在机会。迄今为止,相对罕见的单基因糖尿病形式而非常见的 T2D 已显示出主要的临床影响。然而,高通量测序方法的出现可能预示着罕见和低频变异的发现,这些变异具有更大的转化潜力。